News

Public · Published

EW: PROGRESS supports earlier TAVR evaluation in at-risk moderate AS; CLASP IITR showed PASCAL health-status gains

The CLASP IITR trial met its six-month endpoint, with PASCAL benefits driven mainly by health status. The PROGRESS trial found lower two-year death or heart failure event risk with TAVR in at-risk moderate aortic stenosis, along with strong safety and fewer heart failure hospitalizations.

Published:

Updated:

What happened

The CLASP IITR trial met its six-month endpoint, with PASCAL benefits driven mainly by health status. The PROGRESS trial found lower two-year death or heart failure event risk with TAVR in at-risk moderate aortic stenosis, along with strong safety and fewer heart failure hospitalizations.

Confirmed

Global impact / market context

For Edwards Lifesciences, trial results supporting earlier TAVR use in moderate aortic stenosis could widen the patient group treated with these heart-valve procedures, supporting device revenue. The PASCAL findings reinforce its heart-valve repair portfolio by linking the device to better patient health status.

Analyst inference

These results shape investor expectations for Edwards' structural heart business, where TAVR sales are a key revenue driver. Evidence favoring earlier intervention may support adoption and capital spending by hospitals, while competitors in heart-valve devices face a shifting treatment standard.

Analyst inference

What to watch

  1. CLASP IITR met its six-month endpoint, with PASCAL benefits driven mainly by health status, a measure of how patients feel and function. Confirmed
  2. Watch for regulatory submissions or label expansion requests that would let TAVR be evaluated and used in at-risk moderate aortic stenosis patients. Proposed
  3. Track hospital adoption and capital spending on TAVR programs, since broader treatment of moderate aortic stenosis could raise procedure volumes and Edwards' device revenue. Analyst inference

Evidence

  • Original source link unavailable